EjectDelay® Active Drug Clinical Efficacy- Primary Endpoint (% patients with IELT >2 min)



EjectDelay® Active Drug -Sexual Satisfaction Ratio
Secondary Endpoint :Patient's Diary Questionnaire # 5



EjectDelay® Active Drug–Partner's Sexual Satisfaction Ratio Patient's Diary Questionnaire # 6



EjectDelay® Active Drug- Mean Change in Intra-vaginal Ejaculatory Latency Time (post-hoc analyses) Patient's Diary Questionnaire # 3



EjectDelay® Active Drug- Safety Adverse Event Analysis

- Only 0.42 percent of the EjectDelay® group reported any treatment-related adverse events, compared to 0.27 percent of the placebo group.
- AEs (Mild irritation) were transient and resolved within minutes

	Total	Placebo Gel	Benzocaine 7.5% Gel	Lidocaine 8% Gel
Incidence Rate (%)	**0.97**	**0.27**	**0.42**	**0.27**
Mild	**7**	**2**	**3**	**2**
Moderate	**0**	**0**	**0**	**0**
Severe	**0**	**0**	**0**	**0**

Efficacy & Safety Summary

- Significant clinical benefits of EjectDelay® active drug in Intra-vaginal ejaculation latency time (mean average change= 6.5 minutes)
- EjectDelay® active drug increased partner satisfaction; (80%) versus 56 % in placebo group
- By the end of the study 0.27% (Placebo) and 0.42 % (EjectDelay® active drug) have shown mild adverse events. This difference was not statistically significant
- The only observed adverse event in this study was skin irritation at site of application; AE resolved in 10 to 20 min

Change in Intra-vaginal Ejaculatory Latency Time Dapoxetine vs. Tempe vs. EjectDelay® Active Drug



1. McMahon CG. Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 October; 4(5): 233-251
2. Culley C. PSD 502: A second Phase III, randomized, double-blind, placebo-controlled study in premature ejaculation (PE) patients in the US and Europe, AUA 2010, Abstract# 1493

Side Effects of Dapoxetine in PE patients

% of subjects who experienced various adverse events

Dapoxetine	30 mg as needed	60 mg as needed	Placebo
Nausea	11.0	22.2	2.2
Dizziness	5.8	10.9	2.2
Headache	5.6	8.8	4.8
Diarrhea	3.5	6.9	1.7
Somnolence	3.1	4.7	0.5
Fatigue	2.0	4.1	1.2
Insomnia	2.1	3.9	1.5
Nasopharyngitis	3.2	2.9	2.3

Side Effects of EjectDelay® Active Drug and Tempe in PE patients

- No systemic adverse events were documented for EjectDelay® or Tempe
- 0.42 % of patients treated with EjectDelay® experienced mild irritation of the glans versus 0.27 % in placebo group; skin irritation resolved within 10-20 minutes
- 9.6% of patients reported treatment-related adverse events in the Tempe (PSD502) group and 1.2% in the placebo group, the majority being loss of erection or hypoesthesia
- Both Tempe and EjectDelay® were well tolerated by female partners